Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?
Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:
”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?
March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference
GARDEN Network – Global Hematological Rare Diseases Alliance
In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.
More than a century later, thalassemia remains primarily classified as a globin gene disorder.
That molecular basis remains central.
However, translational evidence is expanding the framework.
Dysregulated hematopoietic stem cell (HSC) biology.
Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.
These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.
This is not a semantic issue. It is a regulatory one.
A stem cell–centered model could impact:
- Mechanism-based endpoint selection
- Biomarker qualification strategies
- Trial population stratification
- Surrogate endpoint validation
- Long-term follow-up architecture
In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.
The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.
We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.
A century after its original description, reassessment may not be disruptive — it may be necessary.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS